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Prognostication in patients with chronic lymphocytic leukemia (CLL) is challenging due to
heterogeneity in clinical course. We hypothesize that constitutional genetic variation affects
disease progression and could aid prognostication. Pooling data from seven studies incor-
porating 842 cases identifies two genomic locations associated with time from diagnosis to
treatment, including 10q26.13 (rs736456, hazard ratio (HR)= 1.78, 95% confidence interval
(CI)= 1.47–2.15; P= 2.71 × 10−9) and 6p (rs3778076, HR= 1.99, 95% CI= 1.55–2.55;
P= 5.08 × 10−8), which are particularly powerful prognostic markers in patients with early
stage CLL otherwise characterized by low-risk features. Expression quantitative trait loci
analysis identifies putative functional genes implicated in modulating B-cell receptor or innate
immune responses, key pathways in CLL pathogenesis. In this work we identify rs736456 and
rs3778076 as prognostic in CLL, demonstrating that disease progression is determined by
constitutional genetic variation as well as known somatic drivers.
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Chronic lymphocytic leukemia (CLL) is a prevalent hema-tological malignancy with approximately 3750 new casesdiagnosed in the United Kingdom every year1. CLL is
characterized by marked clinical and biological heterogeneity
with a proportion of patients having stable, asymptomatic disease
which never requires therapeutic intervention, whilst others suffer
from a progressive disease with associated shortened survival.
Treatment for symptomatic CLL has been transformed by the
advent of highly effective chemoimmunotherapy regimens, B-cell
receptor signaling pathway inhibitors (BCRi) and agents targeting
anti-apoptotic proteins but the majority of patients who progress
to the point of therapeutic intervention have historically experi-
enced CLL-related mortality. However the advent of highly
effective combination regimens utilizing both BCRi and anti-
apoptotic agents may improve patient outcomes2.
Prognostication in early stage CLL and identifying those
patients at risk of progression remains challenging. Numerous
methods of CLL prognostication exist, which range from clinical
assessments to genomic techniques. Clinical assessments include
the Rai3 or Binet4 scores, where adverse outcomes are associated
with increasing tumor load and evidence of marrow failure, and
the CLL international prognostic index (CLL-IPI)5 which utilizes
a combination of clinical and biological characteristics to assess
prognosis6–9. Cases with unmutated immunoglobulin heavy
chain variable region (IGHV) genes10 and those with mutations/
deletions affecting TP53, NOTCH1, and SF3B1 have poor
prognoses11,12, although these alterations are infrequent in newly
diagnosed CLL patients13,14. Once patients progress to sympto-
matic disease then somatic drivers of disease, particularly muta-
tions of TP53 and SF3B1, as well as complex karyotype, become
dominant prognostic markers15,16.
CLL arises from an unidentified cell-of-origin in response to
continued signaling through the BCR either in response to ongoing
antigenic stimulation by auto-antigens or allo-antigens, or is driven
by autonomous BCR activation17. The increased incidence of CLL
in first-degree relatives of affected patients also points to an element
of genetic susceptibility, which has been borne out in large scale
genome-wide association studies (GWAS) which to date have
identified over 40 risk alleles18–25. Given the important genetic
contribution to CLL susceptibility we hypothesized that constitu-
tional genetic variants also contribute to determining risk of disease
progression.
In this work, we conduct a GWAS using data from a large United
Kingdom multicentre cohort study of well characterized pre-
dominantly early-stage CLL cases to identify two risk alleles for
progressive disease in patients with previously untreated disease.
Results
Meta-analysis of CLL genome-wide association studies. We
conducted six genome-wide association studies for single
nucleotide polymorphisms (SNPs) associating with progressive
CLL incorporating cases of European ancestry diagnosed at
clinical centers across the United Kingdom (Supplementary
Fig. 6; Supplementary Table 1). Of these, data on time to first
treatment (TTFT) was available for 755 cases. We combined the
association test statistic for 5199911 autosomal SNPs common to
all 6 GWAS after exclusion of those with an imputation info
(imputation quality) score of <0.9 and a minor allele frequency
(MAF) of <0.025, and conducted a meta-analysis under a fixed-
effects model. Quantile-quantile plots of observed vs. expected P
values for SNPs showed minimal inflation of the test statistic
(λGC= 1.027) excluding the possibility of hidden population sub-
structure or cryptic relatedness (Supplementary Fig. 9).
Pooling data from 6 GWAS identified 5 SNPs at two genomic
locations that surpassed genome-wide significance (P ≤ 5 × 10−8)
for association with time from diagnosis to first treatment (Fig. 1).
The strongest statistical evidence for an association with progressive
CLL was for rs736456 (hazard ratio (HR)= 1.76, 95% confidence
interval (CI)= 1.45–2.14; P= 1.26 × 10−8), which maps to the
TACC2 locus on chromosome 10q26.13 (Fig. 2). The second
strongest association with progressive disease was for rs3778076
(HR= 2.03, 95% CI= 1.58–2.62; P= 3.89 × 10−8) which maps to
the SPDEF and C6ORF106 (ILRUN) genes on chromosome 6p
(Fig. 2). We genotyped rs736456 and rs3778076 in a seventh cohort,
bringing the total number of CLL cases analyzed to 842. Both
markers showed consistent direction and magnitude of effect sizes
across all seven studies with no evidence of heterogeneity (Fig. 3).
There was no evidence of significant interaction between rs736456
and rs3778076 (P= 0.131), suggesting that each locus has an
independent effect on CLL progression. Analysis conditioning on
the lead SNP at each locus showed no evidence for other variants
(P < 10−4) associating with progressive disease (Supplementary
Fig. 10).
Neither the lead SNP on chromosome 10 nor chromosome 6
were significantly associated with post-treatment survival
(rs736456 (chr. 10), HR 1.03, 95% CI 0.79–1.35, P= 0.801;
rs3778076 (chr. 6), HR 0.99, 95% CI 0.70–1.42) (Supplementary
Fig. 11).
rs736456 and rs3778076 predict disease progression in early
stage CLL. In order to further investigate the associations with
progressive disease we stratified patients by disease stage at pre-
sentation and established prognostic markers. rs736456 (chro-
mosome 10) and rs3778076 (chromosome 6) significantly
associate with disease progression in patients with Binet stage A
disease at presentation, but have limited prognostic impact in
patients with Binet stage B and C at presentation (Supplementary
Fig. 12) (P= 3.81 × 10−5 in Binet A and P= 0.12 in Binet B/C for
rs736456 carriers vs. non-carriers; P= 1.93 × 10−9 in Binet A and
P= 0.69 in Binet B/C for rs3778076 carriers vs. non-carriers),
consistent with a specific role in driving progression in early stage
disease. Both genetic markers retained significance in multivariate
models for disease progression restricted to Binet stage A patients
and when adjusted for study in the model (Fig. 4). rs736456 and
rs3778076 were particularly powerful markers for disease pro-
gression in stage A patients when considered together, where
carriers of 1 risk allele (P= 1.4 × 10−7) or 2 or more risk alleles
(P= 7.9 × 10−8) have a significantly shorter time to first treat-
ment compared to non-carriers (Fig. 4c). Whilst not as powerful
as IGHV status, rs736456 and rs3778076 had prognostic utility
approximately equivalent to CD38 status. Moreover, rs736456
and rs3778076 both significantly associate with progressive dis-
ease in patients with otherwise low risk clinical markers,
including IGHV mutation (Supplementary Fig. 13), CD38 nega-
tivity (Supplementary Fig. 14), low β2 microblobulin (Supple-
mentary Fig. 15) and wild-type for TP53 (Supplementary Fig. 16).
As such, rs736456 and rs3778076 are particularly powerful
prognostic markers in analysis restricted to patients with disease
that is Binet stage A, IGHV mutated and CD38 negative (Sup-
plementary Fig. 17). Taken together, these data identify rs736456
and rs3778076 as prognostic for disease progression in patients
with otherwise low risk markers, but which have limited prog-
nostic power in patients with high-risk markers or late stage
disease.
Progressive disease loci at chromosomes 10 and 6. To identify
cis-regulated genes at each locus associated with progressive disease
we interrogated gene expression data derived from a meta-analysis
of 31624 blood samples collated by the eQTLGen consortium26.
Thirteen genes were annotated to within 1Mb of the chromosome
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10 association signal and rs736456 is eQTL for the PLEKHA1 gene
(pleckstrin homology domain-containing family A; TAPP-1)
(Benjamini-Hochberg corrected P-value [PBH]= 1.29 × 10−15)
(Supplementary Table 2). Of the 27 genes annotated to within 1Mb
of the chromosome 6 signal, rs3778076 is eQTL for 5 genes
including most significantly UHRF1BP1 (Ubiquitin-Like Contain-
ing PHD And RING Finger Domains 1-Binding Protein 1) (PBH=
6.73 × 10−139) and ILRUN (Inflammation And Lipid Regulator
With UBA-Like And NBR1-Like Domains; C6ORF106) (PBH=
3.54 × 10−64)(Supplementary Table 3).
Shared risk alleles for CLL etiology and progressive disease.
rs3778076 maps close (103 kb) to an established CLL etiological risk
variant on chromosome 6q21 (rs3800461)20 and the two variants
are in linkage disequilibrium (r2 0.46, D’ 0.91) suggesting they
might drive initial CLL development and subsequent progression to
symptomatic disease via a common mechanism. Consistent with
this hypothesis, rs3800461 is also an eQTL for UHRF1BP1 and
ILRUN (C6ORF106) (Supplementary Table 4), although we cannot
exclude these variants operating through independent mechanisms.
Of other CLL risk variants identified via large scale GWAS18–25,
data on 5 variants did not pass quality control in our study
(rs9815073, rs6858698, rs10069690, rs7944004, rs71597109) and
none of the others were significantly (P < 10−3) associated with
progressive disease (Supplementary Figs. 18–59).
Discussion
CLL susceptibility loci identified to date implicate genes central to
B-cell development, BCR signaling and apoptotic responses20.
These risk alleles may therefore function by promoting the
generation of abnormal pro-B populations or to maintain the
outgrowth of CLL-precursors in response to continuous BCR
signaling. However, the current model would suggest that once
the pre-leukemic CLL clone has established, disease progression
becomes largely dependent on the classic multi-hit model of
oncogenesis where acquired somatic drivers promote clonal
expansion11, thus temporally limiting the impact of constitutional
genetic variants to disease progression at an early stage.
The evidence presented herein suggests that, in addition to
being etiological, constitutional risk alleles contribute to disease
progression in CLL post-diagnosis. Our data suggest that
rs736456 and rs3778076 are powerful prognostic markers in early
stage CLL, but have less impact as disease progresses, predicted to
be due to the acquisition of strongly prognostic somatic altera-
tions which then dominate. Consistent with this model, the
prognostic power of rs3778076 and rs735456 is weaker in patients
with Binet stage B or C disease and in patients with high risk
somatic markers, such as unmutated IGHV or CD38 positivity.
The progressive disease allele at chromosome 10 (rs736456) is
associated with increased expression of PLEKHA1 (pleckstrin
homology domain containing A1; TAPP1) whilst the allele at
chromosome 6 (rs3778076) is associated with increased expres-
sion of ILRUN (Inflammation And Lipid Regulator With UBA-
Like And NBR1-Like Domains; C6ORF106) and UHRF1BP1
(UHRF binding protein 1). PLEKHA1, a plekstrin homology
(PH) adapter protein is a target for phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3K) signaling and a partner for phos-
phatidylinositol 4,5-bisphosphate (PIP2) which regulates the
assembly of signaling complexes at the cell membrane27. PI3K-
mediated signaling is a key element of BCR-mediated signal
transduction, a receptor with a central, etiological role in CLL
Fig. 1 Manhattan plot from chronic lymphocytic leukemia meta-analysis of 6 genome-wide association studies for variants associating with
progressive disease. Manhattan plot of fixed-effects meta-analysis results for time to first treatment (TTFT). Study-specific single nucleotide
polymorphism (SNP) effect sizes were combined using the inverse-variance-weighted approach, and nominal meta P values were calculated based on Z-
score statistics. The x-axis represents SNP coordinates on autosomal chromosomes and the y-axis shows the fixed-effects meta P values in the −log10
scale. All statistical tests were two-sided and red dashed line indicates significance at genome-wide level (P≤ 5 × 10−8). Risk loci for progressive CLL are
annotated with chromosome position and local genes.
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Fig. 2 Regional association and linkage disequilibrium plots for loci associated with progressive CLL. Regional plots of time to first time treatment
(TTFT) survival associations for rs736456 (a) and rs3778076 (b) reaching genome-wide significance (P≤ 5 × 10−8). Study-specific single nucleotide
polymorphism (SNP) effects were combined in a fixed effect model using an inverse-variance-weighted method. Nominal meta-analysis P values were
calculated based on Z-score statistics and all statistical tests were two-sided. Plots show SNP coordinates based on genomic build b37/hg19 on the x-axis,
and −log10 (P values) on the y-axis. Genotyped and imputed SNPs are represented by diamonds and circles, respectively, and are colored according to their
linkage disequilibrium (pairwise r2) with the lead SNP based on the 1000 Genomes European panel. Reference genes in the region are shown in the lower
panel, with arrows indicating transcript direction, dense blocks representing exons and horizontal lines representing introns. Two additional SNPs at
10q26.13 (rs4752676 and rs736457) (a) and one additional SNP at 6p (rs11757517) (b) also reach genome-wide significance in meta-analysis
(Supplementary Figs. 60–62). The symbol for rs11757517 is obscured on the regional plot (b) by the symbol for rs3778076.
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pathogenesis28. Herold and colleagues identified and validated an
8-gene expression signature including PLEKHA1 that predicted
time to first treatment in CLL29. Furthermore, the PLEKHA1
homologous protein TAPP2 is differentially expressed in CLL,
with increased expression in ZAP70 positive/IGHV unmutated
CLL, a subtype associated with enhanced signaling via the BCR
with associated pro-survival effects on cultured CLL-cells30,31.
ILRUN (C6ORF106) regulates interferon regulatory factor 3
(IRF3) signaling which modulates cellular responses to viral
antigens. Given that CLL may arise in response to chronic sti-
mulation of the BCR by viral antigens, constitutional regulation
of an IRF3-dependent response may therefore affect the expan-
sion of CLL-clones32. IRF3 also regulates expression of miR-
15533,34 which is thought to be etiological in a subset of
patients33,35 and also associates with unmutated IGHV and
aggressive disease in CLL36–40.
UHRF1BP1 has been identified as a susceptibility gene for
systemic lupus erythematosus (SLE)41 with differential methyla-
tion affecting regulation of this gene42, however UHRF1BP1 has
not previously been associated with B-cell tumors. An etiological
CLL GWAS identified susceptibility variants mapping to within
the B-cell scaffold protein with ankyrin repeats 1 (BANK1)
gene20. BANK1 is an adapter for BCR signals, modulates CD40
receptor-mediated signaling responses and has also been impli-
cated in SLE and other inflammatory arthropathies43–45. There-
fore, the association of both UHRF1BP1 and BANK1 with CLL
and SLE could imply common etiological factors between the two
diseases. Given that both CLL and SLE are considered to arise, in
part, due to a loss of immunological tolerance to self-antigens or
auto-antigens this may provide further indirect evidence for auto-
antigenic drive in the etiology of CLL.
Collectively the risk alleles identified herein map to genes
known to be regulatory for B-cell development and the control of
autoimmunity supporting the concept that either aberrant BCR
signals and/or a breakdown in normal immunological tolerance
contributes to CLL clonal expansion and the subsequent acqui-
sition of somatic driver mutations.
Many patients with Binet stage A CLL never progress to the
point of therapeutic intervention and the accurate identification
of patients in this group has been the subject of intensive
Fig. 3 Forest plots and survival curves for loci associated with progressive CLL. Panels a and c show forest plots for rs736456 (a) and rs3778076 (c) for
the association with time to first treatment (TTFT) by GWAS. No/events: Number of CLL patients/Number of patients receiving treatment; Eff/Ref: effect/
reference allele; EAF: effect allele frequency; HR: hazard ratio; CI: confidence interval; For each study, allelic dosage was estimated for SNP and included in a
Cox proportional hazard model to estimate HR and 95% CI. Wald-type CIs based on the standard normal distribution were reported here. Squares denote
the per-allele HR, with size proportional to the weight of the study. Pooled HRs derived from both the fixed and random-effects models are indicated by
diamonds with their corresponding meta P values from Wald tests shown in the left parentheses. X-axis label formats include reference sequence (rs)
identifier and chromosome:position (b37). P values for Cochran’s Q test (Phet) and I2 for heterogeneity are shown in parentheses. Panels b and d show
Kaplan–Meier survival plots for TTFT in CLL patients stratified by rs736456 (b) and rs3778076 (d). TTFT is defined as the time from diagnosis of CLL to
treatment or last follow-up without treatment. The number of patients in each group at each timepoint are indicated in the table. Nominal P values from
log-rank tests are shown. All statistical tests were two-sided.
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investigation. Multiple prognostic features and tests have been
described to identify those with a low risk of progressive disease.
Conversely, the identification of high-risk prognostic features in
stage A CLL patients has been used to define a group likely to
need close surveillance as opposed to community monitoring
programmes. The failure, to date, to demonstrate a survival
benefit for early treatment of high-risk asymptomatic patients is
due to an inability to successfully identify an appropriate high-
risk group and also the limits of pre-emptive chemotherapy-based
approaches46. However, with the advent of highly-effective tar-
geted therapies such as BCRi pre-emptive therapy in high-risk
CLL patients is again under investigation47.
Genetic tests for constitutional genetic markers, such as
rs736456 and rs3778076, have the advantage of being easy to
perform, highly reproducible and inexpensive making them ideal
for incorporation into multivariate prognostication models for
disease progression in early stage CLL.
Methods
Patients and ethics. CLL patients were diagnosed at clinical centers in the United
Kingdom, including Bournemouth (Royal Bournemouth Hospital, GWAS 1),
Cardiff (University Hospital of Wales, GWAS 2), Hull (Hull University Teaching
Hospital NHS Trust, GWAS 3 and GWAS 4, study 7), Newcastle (Royal Victoria
Infirmary, GWAS 5) and Gateshead/Sunderland (Queen Elisabeth Hospital/City
Hospitals Sunderland NHS Trust, GWAS 6). Collection of patient samples and
associated clinico-pathological information was undertaken with written informed
consent. All studies were conducted in accordance with the Declaration of Helsinki
and received local institutional review board and/or research ethics approval (Hull
08/H1304/35; Cardiff 02/4806). Newcastle, Gateshead, and Sunderland CLL patient
samples were collected and stored following approval from the Newcastle Academic
Health Partners Biobank (http://www.ncl.ac.uk/biobanks/collections/nbrtb/).
CLL diagnosis, CD38/IGHV analysis. All patients had typical CLL with an
absolute B cell count >5 × 109 L−1 expressing CD5, CD23, CD19 and were diag-
nosed in accordance with World Health Organisation guidelines48 con-
temporaneous to the time of diagnosis. Cases were recruited to each study in the
following time periods: GWAS1 (1970–2005), GWAS2 (1979–2009), GWAS3
(1970–2009), GWAS4 (1997–2013), GWAS5 (1972–2002), GWAS6 (1969–2015),
study 7 (1997–2017). IGHV gene sequences were analyzed using IgBlast (v1.3.0)
(https://www.ncbi.nlm.nih.gov/igblast/) and those with at least 98% homology to
germline were regarded as unmutated10. CD38 expression was determined at each
individual clinical center via flow cytometric analysis of diagnostic samples and a
cut-off of 30% was used for positivity49. Serum β2 microblobulin was performed by
referring centers using locally established and validated immunoassays. Assessment
of deletion 17p and TP53 mutation analysis was in line with ERIC recommenda-
tions on TP53 mutation analysis in chronic lymphocytic leukemia50.
Treatment was initiated in response to standard indications51. Given the historic
nature of the treated cohorts in this study the treatment regimens employed were
predominantly chemotherapeutic (chlorambucil monotherapy, fludarabine
monotherapy, fludarabine, and cyclophosphamide) or chemoimmunotherapeutic
Fig. 4 Multivariate prognostication models for time to first treatment (TTFT) and survival curves in Binet stage A CLL. Study-stratified multivariable
Cox proportional hazard model for TTFT in Binet A CLL patients incorporating rs736456 (a) and rs3778076 (b). Age at diagnosis (continuous), gender
(binary), CD38 (binary), VH (binary) and SNP allelic dosage for the effect allele (continuous) were included together in a study-stratified Cox proportional
hazard model to estimate Hazard ratios (HR) and 95% confidence intervals (CI). CI and nominal P values from Wald tests based on the standard normal
distribution were reported here. Cases with missing data for any of the variables were excluded from multivariate models. c Kaplan–Meier survival plot for
TTFT by number of cumulative risk alleles (0, 1, >1) for rs3778076 and rs736456 in Binet A CLL patients. TTFT is defined as the time from diagnosis of CLL
to treatment or last follow-up without treatment. The number of patients in each group at each timepoint are indicated in the table. Nominal P value from
the log-rank test is shown. All statistical tests were two-sided.
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(chemotherapy in combination with a CD20 monoclonal antibody). A minority of
patients were treated with other regimens including radiotherapy, alemtuzumab,
ibrutinib or ibrutinib in combination with venetoclax.
Unmutated IGHV, CD38-positivity, Binet stage B or C, serum β2 microblobulin
>3.5 mg L−1 and deletion/mutation of TP53 at presentation were all significantly
associated with shorter time to first treatment (TTFT) in univariate analysis
(Supplementary Figs. 1–5; P < 0.05), confirming that established prognostic
markers predict disease progression in patients recruited to this study.
Genotyping and quality control procedures. DNA was extracted from peripheral
blood and genotyped on Illumina OmniExpress arrays (8v1, 8v1-2, or 8v1.3).
Genotypes were determined using Illumina GenomeStudio software (v2.0) (Illu-
mina) with 922269 SNPs common to all three arrays (Supplementary Fig. 6).
Quality control and data analysis were performed using R v3.5.1 and PLINK
v1.9b4.4 (Supplementary Fig. 6). Given that CLL cases were genotyped using DNA
extracted from tissue samples that include leukemic B cells we applied rigorous
quality control to remove variants potentially affected by somatic copy number
alterations. For each GWAS we excluded markers with departure from
Hardy–Weinberg equilibrium (HWE; P ≤ 10−3), a call rate <95% or with sig-
nificant differences in minor allele frequency (P ≤ 10−3) between genotype batches.
Data from all six GWAS were combined for sample quality control processing.
Samples were excluded if the call rate was < 95%, heterozygosity exceeded 3 stan-
dard deviations from the overall mean heterozygosity or were identified as non-
European based on principal components analysis using 1000 genome data as a
reference (Supplementary Fig. 7). Samples were also removed such that there were
no two individuals with estimated relatedness pihat ≥0.1875, with retention of the
sample with the higher call rate. As an additional control check to ensure that the
constitutional variants reported here are not located within recurrent regions of
somatic copy number change we used Nexus Copy Number software 10 (build
version 9665) (BioDiscovery, California) to interrogate B allele frequency and Log
R ratio at variant positions.
Following the exclusion of poor quality markers and samples, haplotypes were
estimated from genotypes using ShapeIT (v2.r790)52 and genome-wide imputation
was performed using the Michigan Imputation Server (https://imputationserver.
sph.umich.edu/index.html) and the Haplotype Reference Consortium reference
haplotype panel (http://www.haplotype-reference-consortium.org/). All variants
with an imputation info score <0.9 were excluded from subsequent analysis.
Genome-wide analysis for markers that predict time to first treatment. The
primary outcome assessed in this study was time to first treatment (TTFT), defined as
the interval between CLL diagnosis and date of first treatment or last follow-up. For
each study, allelic dosage was estimated for the minor allele at each variant position
and included in a cox proportional hazard model to estimate hazard ratio (HR) and
95% confidence interval (CI). Variants were included in the meta-analysis if they had
results from all six studies. Study-specific single nucleotide polymorphism (SNP)
effects were combined using an inverse-variance-weighted method (fixed effects
model) and the DerSimonian–Laird approach (random effects model) using R
metafor package (v2.4-0)53. SNPs with fixed-effect P values of ≤5 × 10−8 were deemed
significant at genome-wide level. Cochran’s Q test and I2 were used to assess the
heterogeneity across studies. Regional plots were generated using LocusZoom (V1.4)
downloaded from https://github.com/statgen/locuszoom-standalone.
To test for secondary signals in regions achieving genome-wide significance we
carried out conditional analysis on the index SNP by study and then combined
individual conditional effect sizes from 6 studies under a fixed effects model. SNPs
with a conditional meta P value <10−4 were considered independent of the
index SNP.
Heterogeneity of Kaplan-Meier survival curves was assessed by the log-rank test,
including tests for established prognostic markers, the most likely index SNP
genotypes (for genotypes with posterior probabilities >0.9), combined groups of
established prognostic markers/SNPs and combined SNP genotypes. For joint
analyses, pairwise log-rank tests, with false discovery rate (FDR) corrections for
multiple testing, were used to test for significant differences between survival curves.
Study-stratified multivariate Cox proportional hazard models incorporating
established prognostic markers including IGHV and CD38 status were used to
determine the impact of variants on disease progression. Cases with missing data
for any of the variables were excluded from multivariate models.
A secondary outcome was post-treatment survival, defined as the interval
between first treatment for CLL-related symptoms and death or last follow-up.
Data on post-treatment survival were available on 390 CLL cases from six studies
(GWAS1-6), with 231 deaths and 159 censored at last follow-up.
Technical validation of variants associating with progressive CLL. rs3778076
was directly genotyped in all six GWAS and rs736456 was imputed to high quality
in all six GWAS (info score 0.974–0.985). Fidelity of array genotyping and imputed
dosages was confirmed using Sanger sequencing in a subset of samples for each
sentinel variant with concordance of 100% for all variants (Supplementary Fig. 8).
rs3778076 and rs736456 were directly genotyped in study 7 using Sanger
sequencing.
Expression quantitative trait loci analysis. To identify cis expression quantitative
trait loci (eQTLs) we made use of summary data from the eQTLGen Consortium
for whole blood, which incorporates 37 independent datasets derived from a total
of 31684 individuals (http://www.eqtlgen.org/cis-eqtls.html)26. Benjamini-
Hochberg (BH)-adjusted P values were estimated for each gene annotated to within
1 Mb of rs736456 on 10q26.13 and rs3778076 on 6p.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Genome-wide association summary statistics (Lin_TTFT_CLLmetaAssoc.txt) are
available for download from https://doi.org/10.25405/data.ncl.12136365. eQTL data is
available from the eQTLGen consortium via http://www.eqtlgen.org/cis-eqtls.html (2019-
12-11-cis-eQTLsFDR-ProbeLevel-CohortInfoRemoved-BonferroniAdded.txt.gz). The
remaining data are contained within the supplementary information files or available
from the authors upon reasonable request. Source data are provided with this paper.
Received: 10 October 2019; Accepted: 16 December 2020;
References
1. HMRN. Haematological Malignancy Research Network. https://www.hmrn.
org/ (2018).
2. Hillmen, P. et al. Ibrutinib plus venetoclax in relapsed/refractory chronic
lymphocytic leukemia: the CLARITY study. J. Clin. Oncol. JCO1900894,
https://doi.org/10.1200/JCO.19.00894 (2019).
3. Rai, K. R. et al. Clinical staging of chronic lymphocytic leukemia. Blood 46,
219–234 (1975).
4. Binet, J. L. et al. A new prognostic classification of chronic lymphocytic leukemia
derived from a multivariate survival analysis. Cancer 48, 198–206 (1981).
5. International, C. L. L. I. P. I. W. G. An international prognostic index for
patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of
individual patient data. Lancet Oncol. 17, 779–790 (2016).
6. Lin, K. et al. Relationship between p53 dysfunction, CD38 expression, and IgV
(H) mutation in chronic lymphocytic leukemia. Blood 100, 1404–1409 (2002).
7. Crespo, M. et al. ZAP-70 expression as a surrogate for immunoglobulin-
variable-region mutations in chronic lymphocytic leukemia. N. Engl. J. Med.
348, 1764–1775 (2003).
8. Bulian, P. et al. CD49d is the strongest flow cytometry-based predictor of overall
survival in chronic lymphocytic leukemia. J. Clin. Oncol. 32, 897–904 (2014).
9. Dohner, H. et al. Genomic aberrations and survival in chronic lymphocytic
leukemia. N. Engl. J. Med. 343, 1910–1916 (2000).
10. Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G. & Stevenson, F. K.
Unmutated Ig V(H) genes are associated with a more aggressive form of
chronic lymphocytic leukemia. Blood 94, 1848–1854 (1999).
11. Landau, D. A. et al. Mutations driving CLL and their evolution in progression
and relapse. Nature 526, 525–530 (2015).
12. Zenz, T. et al. TP53 mutation and survival in chronic lymphocytic leukemia. J.
Clin. Oncol. 28, 4473–4479 (2010).
13. Zainuddin, N. et al. TP53 Mutations are infrequent in newly diagnosed
chronic lymphocytic leukemia. Leuk. Res. 35, 272–274 (2011).
14. Gunnarsson, R. et al. Large but not small copy-number alterations correlate to
high-risk genomic aberrations and survival in chronic lymphocytic leukemia:
a high-resolution genomic screening of newly diagnosed patients. Leukemia
24, 211–215 (2010).
15. Stilgenbauer, S. et al. Gene mutations and treatment outcome in chronic
lymphocytic leukemia: results from the CLL8 trial. Blood 123, 3247–3254 (2014).
16. Herling, C. D. et al. Complex karyotypes and KRAS and POT1 mutations
impact outcome in CLL after chlorambucil-based chemotherapy or
chemoimmunotherapy. Blood 128, 395–404 (2016).
17. Burger, J. A. & Chiorazzi, N. B cell receptor signaling in chronic lymphocytic
leukemia. Trends Immunol. 34, 592–601 (2013).
18. Crowther-Swanepoel, D. et al. Common variants at 2q37.3, 8q24.21, 15q21.3
and 16q24.1 influence chronic lymphocytic leukemia risk. Nat. Genet. 42,
132–136 (2010).
19. Speedy, H. E. et al. A genome-wide association study identifies multiple
susceptibility loci for chronic lymphocytic leukemia. Nat. Genet. 46, 56–60 (2014).
20. Law, P. J. et al. Genome-wide association analysis implicates dysregulation of
immunity genes in chronic lymphocytic leukaemia. Nat. Commun. 8, 14175
(2017).
21. Berndt, S. I. et al. Genome-wide association study identifies multiple risk loci
for chronic lymphocytic leukemia. Nat. Genet. 45, 868–876 (2013).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20822-9 ARTICLE
NATURE COMMUNICATIONS |          (2021) 12:665 | https://doi.org/10.1038/s41467-020-20822-9 | www.nature.com/naturecommunications 7
22. Di Bernardo, M. C. et al. A genome-wide association study identifies six
susceptibility loci for chronic lymphocytic leukemia. Nat. Genet. 40,
1204–1210 (2008).
23. Berndt, S. I. et al. Meta-analysis of genome-wide association studies discovers
multiple loci for chronic lymphocytic leukemia. Nat. Commun. 7, 10933 (2016).
24. Slager, S. L. et al. Common variation at 6p21.31 (BAK1) influences the risk of
chronic lymphocytic leukemia. Blood 120, 843–846 (2012).
25. Slager, S. L. et al. Genome-wide association study identifies a novel
susceptibility locus at 6p21.3 among familial CLL. Blood 117, 1911–1916
(2011).
26. Võsa, U. et al. Unraveling the polygenic architecture of complex traits using
blood eQTL meta-analysis. Preprint at bioRxiv https://doi.org/10.1101/447367
(2018).
27. Marshall, A. J., Krahn, A. K., Ma, K., Duronio, V. & Hou, S. TAPP1 and
TAPP2 are targets of phosphatidylinositol 3-kinase signaling in B cells:
sustained plasma membrane recruitment triggered by the B-cell antigen
receptor. Mol. Cell Biol. 22, 5479–5491 (2002).
28. Hoellenriegel, J. et al. The phosphoinositide 3′-kinase delta inhibitor, CAL-
101, inhibits B-cell receptor signaling and chemokine networks in chronic
lymphocytic leukemia. Blood 118, 3603–3612 (2011).
29. Herold, T. et al. An eight-gene expression signature for the prediction of
survival and time to treatment in chronic lymphocytic leukemia. Leukemia 25,
1639–1645 (2011).
30. Costantini, J. L. et al. TAPP2 links phosphoinositide 3-kinase signaling to B-
cell adhesion through interaction with the cytoskeletal protein utrophin:
expression of a novel cell adhesion-promoting complex in B-cell leukemia.
Blood 114, 4703–4712 (2009).
31. Allsup, D. J. et al. B-cell receptor translocation to lipid rafts and associated
signaling differ between prognostically important subgroups of chronic
lymphocytic leukemia. Cancer Res. 65, 7328–7337 (2005).
32. Kostareli, E. et al. Molecular evidence for EBV and CMV persistence in a
subset of patients with chronic lymphocytic leukemia expressing stereotyped
IGHV4-34 B-cell receptors. Leukemia 23, 919–924 (2009).
33. Tarassishin, L. et al. Interferon regulatory factor 3 inhibits astrocyte
inflammatory gene expression through suppression of the proinflammatory
miR-155 and miR-155*. Glia 59, 1911–1922 (2011).
34. Tian, W. L. et al. IRF3 is involved in human acute myeloid leukemia through
regulating the expression of miR-155. Biochem Biophys. Res. Commun. 478,
1130–1135 (2016).
35. Marton, S. et al. Small RNAs analysis in CLL reveals a deregulation of miRNA
expression and novel miRNA candidates of putative relevance in CLL
pathogenesis. Leukemia 22, 330–338 (2008).
36. Cui, B. et al. MicroRNA-155 influences B-cell receptor signaling and associates
with aggressive disease in chronic lymphocytic leukemia. Blood 124, 546–554
(2014).
37. Vargova, K. et al. MiR-155/miR-150 network regulates progression through the
disease phases of chronic lymphocytic leukemia. Blood Cancer J. 7, e585 (2017).
38. Guinn, D. et al. miR-155 expression is associated with chemoimmunotherapy
outcome and is modulated by Bruton’s tyrosine kinase inhibition with
Ibrutinib. Leukemia 29, 1210–1213 (2015).
39. Ferrajoli, A. et al. Prognostic value of miR-155 in individuals with monoclonal
B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood
122, 1891–1899 (2013).
40. Calin, G. A. et al. A MicroRNA signature associated with prognosis and
progression in chronic lymphocytic leukemia. N. Engl. J. Med. 353, 1793–1801
(2005).
41. Gateva, V. et al. A large-scale replication study identifies TNIP1, PRDM1,
JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus.
Nat. Genet. 41, 1228–1233 (2009).
42. Imgenberg-Kreuz, J. et al. DNA methylation mapping identifies gene
regulatory effects in patients with systemic lupus erythematosus. Ann. Rheum.
Dis. 77, 736–743 (2018).
43. Aiba, Y. et al. BANK negatively regulates Akt activation and subsequent B cell
responses. Immunity 24, 259–268 (2006).
44. Kozyrev, S. V. et al. Functional variants in the B-cell gene BANK1 are
associated with systemic lupus erythematosus. Nat. Genet. 40, 211 (2008).
45. Genin, E. et al. Epistatic interaction between BANK1 and BLK in rheumatoid
arthritis: results from a large trans-ethnic meta-analysis. PLoS ONE 8, e61044
(2013).
46. Cymbalista, F. et al. Early versus deferred treatment with combined
fludarabine, cyclophosphamide and rituximab (fcr) improves event-free
survival in patients with high-risk binet stage a chronic lymphocytic
leukemia–first results of a randomized German-French cooperative Phase III
Trial. Blood 122, 524–524 (2013).
47. Langerbeins, P. et al. The CLL12 trial protocol: a placebo-controlled double-
blind Phase III study of ibrutinib in the treatment of early-stage chronic
lymphocytic leukemia patients with risk of early disease progression. Future
Oncol. 11, 1895–1903 (2015).
48. Swerdlow S. H., et al. WHO Classification of Tumours of Haematopoietic and
Lymphoid Tissues. Vol. 2 (ed. Swerdlow S. H.) Ch. 13, 216 (International
Agency for Research on Cancer, 2017).
49. Matrai, Z. et al. CD38 expression and Ig VH gene mutation in B-cell chronic
lymphocytic leukemia. Blood 97, 1902–1903 (2001).
50. Pospisilova, S. et al. ERIC recommendations on TP53 mutation analysis in
chronic lymphocytic leukemia. Leukemia 26, 1458–1461 (2012).
51. Hallek, M. et al. Guidelines for the diagnosis and treatment of chronic
lymphocytic leukemia: a report from the International Workshop on Chronic
Lymphocytic Leukemia updating the National Cancer Institute-Working
Group 1996 guidelines. Blood 111, 5446–5456 (2008).
52. Delaneau, O., Marchini, J. & Zagury, J. F. A linear complexity phasing method
for thousands of genomes. Nat. Methods 9, 179–181 (2011).
53. Viechtbauer, W. Conducting Meta-Analyses in R with the metafor Package. J.
Statist. Software 36, 48 (2010).
Acknowledgements
This work was funded by Blood Cancer UK (formely Bloodwise) (#06002 and #13044 to
J.M.A.). J.M.A. is recipient of an Oncology/Haematology Fellowship from Gilead Phar-
maceuticals and C.E. received funding from JGW Patterson Foundation. This work was
supported by Cancer Research UK (C2115/A21421). E.W. and G.S. received funding
from Blood Cancer UK (#14024). A.S. was partly funded by the National Institute for
Health Research Oxford Biomedical Research Centre; the views and opinions expressed
are those of the authors and do not necessarily reflect those of the National Institute for
Health Research, the UK National Health Service, the UK Department of Health or the
Universities of Oxford. We are grateful for the support of the Clinical Trials Research
Unit at The University of Leeds and the Hull York Medical School, University of Hull for
funding the Daisy Tumour Bank.
Author contributions
W.-Y.L. collated data, conducted data analysis and drafted the manuscript. S.E.F., N.S.,
C.E., T.R., E.W., C.S., G. Strathdee, T.M.-F., R.P., H.Mearns, T.B., R.S.H., H.Marr, J.W.,
G.Summerfield, S.M., A.P., C.P., C.F., F.F., M.J.S.D., S.J., A.Sellors, A.Schuh, P.R., D.O.,
J.B., S.R., A.B., L.C., P.E., P.H., and G.P. generated/collated data and/or advised on data a
nalysis. J.M.A. and D.J.A. designed the project, generated data, analyzed data, directed
the research and drafted the manuscript. J.M.A. also obtained funding. All authors
contributed to the final version of the manuscript.
Competing interests
The authors declare no competing interests.
Additional information
The online version contains supplementary material available at https://doi.org/10.1038/
s41467-020-20822-9.
Correspondence and requests for materials should be addressed to D.J.A. or J.M.A.
Peer review information Nature Communications thanks Stephen J. Chanock and the
other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer
reviewer reports are available.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2021
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20822-9
8 NATURE COMMUNICATIONS |          (2021) 12:665 | https://doi.org/10.1038/s41467-020-20822-9 | www.nature.com/naturecommunications
